Experts discuss strategies to reduce treatment-related toxicities in bispecific antibody treatments, emphasizing clarity on dosing, hydration, and safety concerns.
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari discusses the development and execution of innovative protocols to reduce treatment-related toxicities in patients receiving bispecific antibodies. Ali shares insights into managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome, emphasizing the evolving understanding and tips gathered over time. Strategies include prophylactic tocilizumab, patients taking home dexamethasone, maintaining hydration, and adjusting intravenous infusion rates. The conversation explores potential changes in dosing frequency for myeloma bispecifics and addresses the balance between therapeutic efficacy and patient tolerability. The speakers emphasize the importance of education, shared decision-making, and ongoing learning in optimizing bispecific antibody treatments for patients with lymphomas.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.